NURIX THERAPEUTICS INC (NRIX)
Sector: Health Care
2026 Annual Meeting Analysis
NURIX THERAPEUTICS INC · Meeting: May 15, 2026
Directors FOR
3
Directors AGAINST
0
Say on Pay
FOR
Auditor
FOR
Director Elections
Election of Class III Directors
Dr. Sands has served as CEO and director since 2014 and brings deep scientific and leadership expertise; NRIX's 3-year stock return of +64.4% outperforms the peer group median by +78.1 percentage points, well above the 65pp threshold required to trigger an against vote, and no overboarding, attendance, or independence concerns apply.
Dr. Dansey joined the board in November 2025 — less than 24 months ago — and is therefore fully exempt from the TSR performance trigger under policy; he brings highly relevant oncology drug development expertise from senior roles at Pfizer, Seagen, and Merck, and no attendance or independence concerns are noted, though shareholders should note he serves on six other boards (Bicycle Therapeutics, Inovio, Atida Bio, MycRX Pharma, Ottimo Pharma, and Shasqi) which approaches the overboarding threshold but does not trigger a No vote since none appear to be public company seats that would push him to four or more public boards.
Mr. Silva has served since October 2021 and brings extensive biotechnology finance experience including a long tenure as Chief Accounting Officer at Vertex Pharmaceuticals; he serves as Audit Committee chair and qualifies as an audit committee financial expert, the TSR trigger does not apply given NRIX's strong 3-year outperformance of peers, and no overboarding or attendance concerns are present.
All three Class III director nominees — CEO Arthur Sands, newly appointed oncology expert Roger Dansey, and finance veteran Paul Silva — receive a FOR vote. NRIX's 3-year stock return of +64.4% outperforms the disclosed compensation peer group median by +78.1 percentage points, far exceeding the 65pp threshold needed to trigger an against vote, so the TSR trigger does not fire for any director. Dr. Dansey is additionally protected by the 24-month new-director exemption. No overboarding, attendance, independence, or qualification concerns were identified.
Say on Pay
✓ FORCEO
Arthur T. Sands
Total Comp
$6,374,138
Prior Support
81.4%%
CEO total compensation of approximately $6.4 million is reasonable for a pre-commercial biotechnology company of NRIX's size and stage, and the pay mix is strongly performance-oriented — the proxy discloses that 89% of the CEO's target compensation is variable and at-risk, well above the 50-60% minimum required by policy. The pay-for-performance alignment check also passes: NRIX's 3-year stock return of +64.4% outperforms the XBI — SPDR S&P Biotech ETF by approximately +2.9 percentage points, meaning shareholders have received meaningful positive returns broadly in line with the biotech sector. Prior year say-on-pay support was 81.4%, above the 70% threshold that would require visible remediation, and the company maintains a clawback policy compliant with SEC and Nasdaq rules.
Auditor Ratification
✓ FORAuditor
PricewaterhouseCoopers LLP
Tenure
N/A
Audit Fees
$1,944,390
Non-Audit Fees
$2,000
Non-audit fees of $2,000 represent less than 0.1% of audit fees of $1,944,390, far below the 50% threshold that would raise independence concerns; PricewaterhouseCoopers is a Big 4 firm fully appropriate for a $1.5 billion market cap company; auditor tenure is not disclosed in the filing so the tenure trigger cannot fire, and no material restatements were identified.
Overall Assessment
The 2026 NRIX annual meeting features three straightforward proposals — director elections, auditor ratification, and say-on-pay — all of which receive a FOR vote under this policy. NRIX's strong 3-year stock performance, low non-audit fee ratio, reasonable and heavily performance-weighted executive pay, and solid prior say-on-pay support of 81.4% provide no basis for any against votes across the ballot.
Compensation Peer Group
21 companies disclosed in 2026 proxy filing